Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00464633




Registration number
NCT00464633
Ethics application status
Date submitted
20/04/2007
Date registered
23/04/2007
Date last updated
12/02/2013

Titles & IDs
Public title
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
Scientific title
A Multicenter, Open-label, Single Arm Study of Weekly Alvocidib in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising From CLL
Secondary ID [1] 0 0
2006-006152-34
Secondary ID [2] 0 0
EFC6663
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Leukemia, Lymphocytic, Chronic 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - alvocidib

Experimental: Alvocidib - Cycles with 4-week treatment with alvocidib followed by 2-week rest period for up to a maximum of 6 cycles


Treatment: Drugs: alvocidib
1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion
Then, every treatment week, depending upon the patient's objective response to initial therapy:
30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or
30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Best overall objective response rate
Timepoint [1] 0 0
Up to a maximum of 6 cycles
Secondary outcome [1] 0 0
Progression-free survival
Timepoint [1] 0 0
Up to a maximum of 6 cycles
Secondary outcome [2] 0 0
Duration of objective response
Timepoint [2] 0 0
Up to a maximum of 6 cycles
Secondary outcome [3] 0 0
Overall survival
Timepoint [3] 0 0
Up to a maximum of 6 cycles
Secondary outcome [4] 0 0
Overview of adverse events
Timepoint [4] 0 0
from study drug administration up to 30 days after last study drug administration

Eligibility
Key inclusion criteria
- Patient must have documentation of histologically confirmed and measurable Chronic
Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) arising from CLL;

- Patient must have symptomatic and progressive disease;

- Patient must have received prior alkylating agent(s) and be fludarabine refractory;

- Patient must have the adequate organ functions;

- Patient's Eastern Cooperative Oncology Group performance (ECOG) status must be 0-2;
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patient with de novo PLL;

- Patient with secondary malignancy that will limit survival =5 years;

- Patient with prior allogenic or autologous bone marrow transplant or peripheral blood
stem cell transplant =12 months;

- Patient receiving an investigational agent or an approved agent for an investigational
purpose within last 4 weeks prior to study entry;

- Patient with known history of glucose-6-phosphate dehydrogenase deficiency;

- Patient with autoimmune hemolytic anemia;

- Patient with known Central Nervous System involvement;

- Patient with active, uncontrolled serious bacterial, viral or fungal infections

The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2011
Sample size
Target
Accrual to date
Final
165
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Sanofi-Aventis Investigational Site Number 036001 - St Leonards
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Illinois
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
Belgium
State/province [10] 0 0
Brugge
Country [11] 0 0
Belgium
State/province [11] 0 0
Bruxelles
Country [12] 0 0
Belgium
State/province [12] 0 0
Gent
Country [13] 0 0
Belgium
State/province [13] 0 0
Leuven
Country [14] 0 0
Belgium
State/province [14] 0 0
Yvoir
Country [15] 0 0
France
State/province [15] 0 0
Paris Cedex 13
Country [16] 0 0
France
State/province [16] 0 0
Pierre Benite Cedex
Country [17] 0 0
France
State/province [17] 0 0
Tours
Country [18] 0 0
Germany
State/province [18] 0 0
Kiel
Country [19] 0 0
Germany
State/province [19] 0 0
Köln
Country [20] 0 0
Germany
State/province [20] 0 0
Ulm
Country [21] 0 0
Italy
State/province [21] 0 0
Bologna
Country [22] 0 0
Italy
State/province [22] 0 0
Milano
Country [23] 0 0
Netherlands
State/province [23] 0 0
Amsterdam
Country [24] 0 0
Netherlands
State/province [24] 0 0
Groningen
Country [25] 0 0
Netherlands
State/province [25] 0 0
Rotterdam
Country [26] 0 0
Puerto Rico
State/province [26] 0 0
San Juan
Country [27] 0 0
United Kingdom
State/province [27] 0 0
Aberdeen
Country [28] 0 0
United Kingdom
State/province [28] 0 0
Birmingham
Country [29] 0 0
United Kingdom
State/province [29] 0 0
Bournemouth

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Multicenter, open-label, study of alvocidib in previously treated chronic lymphocytic
leukemia patients.

Primary objective is to determine overall response rate.

The secondary objectives are:

- to assess overall safety,

- to assess duration of response, progression free survival, and overall survival.

Clinical benefit and pharmacokinetics parameters are also evaluated.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00464633
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00464633